Table 3: KRAS and sensitivity to anti-EGFR agents in phase III trial.

TrialAnti-EGFR agentTotal number of patients ( 𝑛 ) Patients tested for KRAS ( 𝑛 ) KRAS mutant 𝑛 (%)Survival in KRAS mutant (HR)

TRIBUTE [46]Gefitinib107926455 (21)2.1*
BR. 21 [47]Erlotinib73120630 (15)1.67
SATURN [48]Erlotinib 88949390 (18)0.79
ATLAS [15]Erlotinib768NRNR0.92
INTEREST [49]Gefitinib146627549 (18)0.91
FLEX [57]Cetuximab112537972 (19)1.0
BMS099 [56]Cetuximab67620235 (17)0.95

HR: hazard ratio; NR: not reported. *Statistically significant.